ACM
ALDR

Asymmetry Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Asymmetry Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-92,518
Closed -$1.06M – 43
2017
Q4 		$1.06M Sell
92,518
-12,710
-12% -$142K 1.44% 21
2017
Q3 		$1.29M Sell
105,228
-61,524
-37% -$641K 1.49% 21
2017
Q2 		$1.91M Buy
166,752
+127,056
+320% +$2.35M 2.26% 16
2017
Q1 		$826K Buy
+39,696
New +$879K 1.15% 20

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Asymmetry Capital Management's ALDR Position: Q1 2018 in Review

Asymmetry Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 92,518 shares — an estimated $1.06M sold.

Asymmetry Capital Management first reported a position in ALDR in Q1 2017 and held it in 4 quarters. The position peaked at $1.91M in Q2 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Asymmetry Capital Management reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 92,518 Alder Biopharmaceuticals shares in Q1 2018, an estimated $1.06M.
  • Asymmetry Capital Management first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Asymmetry Capital Management's Alder Biopharmaceuticals position peaked at $1.91M in Q2 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Asymmetry Capital Management's 13F filing for Q1 2018, filed 9 May 2018.